Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)

Oppenheimer analyst Hartaj Singh maintained a Hold rating on Oncternal Therapeutics (ONCT – Research Report) today. The company’s shares closed yesterday at $8.69.

According to TipRanks, Singh is a 5-star analyst with an average return of 10.9% and a 43.85% success rate. Singh covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Sarepta Therapeutics, and Biomea Fusion.

Currently, the analyst consensus on Oncternal Therapeutics is a Moderate Buy with an average price target of $26.50.

The company has a one-year high of $13.14 and a one-year low of $5.57. Currently, Oncternal Therapeutics has an average volume of 10.57K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ONCT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oncternal Therapeutics (ONCT) Company Description:

Oncternal Therapeutics, Inc. is a clinical-stage oncology company, which develops a diverse pipeline of treatments for cancers with critically unmet medical need. Its focus is on drug development on promising yet untapped biological pathways implicated in cancer progression. The company was founded in 1997 and is headquartered in San Diego, CA.